| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
TTNPB (AGN-191183; Ro 13 7410; AGN 191183; Arotinoid Acid, Ro13-7410, AGN191183) is a potent RAR (retinoic acid receptor) agonist with potential antitumor activity. It inhibits the binding of [3H]tRA to human RARα, β, and γ with IC50s of 5.1 nM, 4.5 nM, and 9.3 nM, respectively. TTNPB inhibits chondrogenesis with IC50 value of 0.14nM when using mouse limb bud cell cultures. The action of TTNPB results from binding to nuclear receptors. TTNPB can competes with [3H]tRA and prevent them from binding to mRARα, mRARβ and mRARγ with IC50 values of 3.8nM, 4nM and 4.5nM, respectively.
| ln Vitro |
For human RARα, β, and γ, TTNPB has IC50s of 3.8 nM, 4 nM, and 4.5 nM, respectively, which inhibits [3H]tRA binding. TTNPB, whose IC50 is 1800 nM, competes with CRABPI for the binding of [3H]tRA [1].
|
||
|---|---|---|---|
| ln Vivo |
Hyaline cartilage tissue is formed in vivo when TTNPB (Ro 13-7410) (GMP) (100 nM) and Laduviglusib are combined [2].
|
||
| Animal Protocol |
|
||
| References |
[1]. Pignatello MA, et al. Multiple factors contribute to the toxicity of the aromatic retinoid, TTNPB (Ro 13-7410): binding affinities and disposition. Toxicol Appl Pharmacol. 1997 Feb;142(2):319-27
|
| Molecular Formula |
C24H28O2
|
|
|---|---|---|
| Molecular Weight |
348.48
|
|
| CAS # |
71441-28-6
|
|
| Related CAS # |
TTNPB;71441-28-6
|
|
| SMILES |
O=C(O)C1=CC=C(/C=C(C2=CC=C3C(C)(C)CCC(C)(C)C3=C2)\C)C=C1
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 1.25 mg/mL (3.59 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (3.59 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8696 mL | 14.3480 mL | 28.6961 mL | |
| 5 mM | 0.5739 mL | 2.8696 mL | 5.7392 mL | |
| 10 mM | 0.2870 mL | 1.4348 mL | 2.8696 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|---|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
